Predictive oncology stock.

Predictive Oncology Inc. EAGAN, Minn., March 09, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a science-driven company leveraging its proprietary artificial intelligence and ...

Predictive oncology stock. Things To Know About Predictive oncology stock.

Shares of Predictive Oncology Inc. (NASDAQ:POAI – Get Free Report) passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $3.95 and traded ...Predictive Oncology Inc. (POAI) is a science-driven company that leverages its AI and machine learning capabilities to accelerate oncologic drug discovery and enable drug development. The stock price, news, quote and history of POAI are shown on Yahoo Finance, as well as related research and analysis.The estimated Net Worth of J Melville Engle is at least $70.1 Thousand dollars as of 24 May 2022. Mr Engle owns over 159,500 units of Predictive Oncology stock worth over $67,120 and over the last 14 years he sold POAI stock worth over $0. In addition, he makes $3,000 as Chairman & CEO at Predictive Oncology.Nov 24, 2023 · Stock analysis for Predictive Oncology Inc (POAI:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Predictive Oncology. POAI. $3.09 ... as of November 29 4:00:00 PM EST. Predictive Oncology (POAI) Stock Price Performance. Predictive Oncology (POAI) Stock Key Data. Summary Additional Data ...

The estimated Net Worth of J Melville Engle is at least $103 Thousand dollars as of 24 May 2022. Mr Engle owns over 159,500 units of Predictive Oncology stock worth over $99,663 and over the last 14 years he sold POAI stock worth over $0. In addition, he makes $3,000 as Chairman & CEO at Predictive Oncology.Predictive Oncology Inc. is focused on applying artificial intelligence to personalized medicine and drug discovery. Its operating business unit consists of Helomics, TumorGenesis and Skyline Medical. Predictive Oncology Inc., formerly known as Precision Therapeutics Inc., is based in MINNEAPOLIS. Stock Name. Country.

Predictive Oncology appoints Bernard A. Harris, Jr., MD, MBA, venture capitalist and former NASA astronaut to serve on the company’s Business… Liked by Bob Myers Some of you know it as ...Predictive Oncology Inc. Watch list After Hours Last Updated: Nov 13, 2023 7:52 p.m. EST Delayed quote $ 3.0500 -0.14 -4.39% After Hours Volume: 35 Advanced …

Predictive Oncology Inc stock performance at a glance. Check Predictive Oncology Inc’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value.Predictive Oncology Inc. is focused on applying artificial intelligence to personalized medicine and drug discovery. Its operating business unit consists of Helomics, TumorGenesis and Skyline Medical. Predictive Oncology Inc., formerly known as Precision Therapeutics Inc., is based in MINNEAPOLIS. Stock Name. Country.Predictive Oncology (NASDAQ: POAI) is an early-stage AI pharma stock with a differentiated business model.The company owns a biorepository of tumor samples, a lab and a good manufacturing practice ...The latest price target for Predictive Oncology ( NASDAQ: POAI) was reported by HC Wainwright & Co. on Wednesday, June 30, 2021. The analyst firm set a price target for 5.00 expecting POAI to rise ...

This article will tell you the best AI stocks under $1 to buy right now! ... Predictive Oncology is a Minnesota-based data and AI-driven discovery services company providing predictive models of tumor drug response. One of the subsidiaries of Predictive Oncology, TumorGenesis, utilizes specific and highly differentiated methods to grow …

With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.

The estimated Net Worth of Carl I. Schwartz is at least $10.3 Million dollars as of 22 October 2020. Dr Schwartz owns over 640 units of Predictive Oncology stock worth over $9,893,634 and over the last 7 years he sold POAI stock worth over $544. In addition, he makes $433,000 as CEO & Director at Predictive Oncology.TipRanksThe Predictive Oncology Inc ( POAI) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $5.0628, representing a +68.20% increase from the current price of $3.01. The highest analyst price target is $9.9664, and the lowest is $0.1593. Based on our technical indicators, the current sentiment ...Predictive Oncology Inc. is focused on applying artificial intelligence to personalized medicine and drug discovery. Its operating business unit consists of Helomics, TumorGenesis and Skyline Medical. Predictive Oncology Inc., formerly known as Precision Therapeutics Inc., is based in MINNEAPOLIS. Stock Name. Country. Predictive Oncology Market Cap: 12.59M, Enterprise value: N/A, P/E: -0.82, PEG ratio: -0.01, EPS: -3.13, Revenue: 1.80M, EBITDA: -10.25M, Income: -33.59M, ...Fiscal Q3 2023 ended 9/30/23. Reported on 11/14/23. Get the latest Predictive Oncology Inc (POAI) real-time quote, historical performance, charts, and other financial information …

December 01, 2021 at 08:31 am EST. EAGAN, Minn., Dec. 01, 2021 (GLOBE NEWSWIRE) -- Predictive Oncology, (POAI), a knowledge-driven company focused on applying artificial intelligence (AI) to develop personalized cancer therapies, today announced the acquisition of zPREDICTA, a company pioneering tumor-specific in vitro 3D cell culture models ...On average, Predictive Oncology executives and independent directors trade stock every 71 days with the average trade being worth of $99,350. The most recent stock trade was executed by Robert L Myers on 25 September 2023, trading 1,667 units of POAI stock currently worth $5,334.Predictive Oncology (NASDAQ:POAI) on Thursday said it would effect a 1-for-20 reverse stock split.The stock split will become effective on April 24. "The reverse stock split is primarily intended ...Aug 10, 2023 · Predictive Oncology recorded revenue of $490,110 in the second quarter of 2023, compared to $371,591 in 2022. Sales of Streamway related products and services by our Eagan operating segment were ... 0.73%. $39.94B. Astellas Pharma Inc. -4.37%. ¥3.42T. PYXS | Complete Pyxis Oncology Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Nov 14, 2023 · Predictive Oncology recorded revenue of $715,056 in the third quarter of 2023, compared to $455,827 for the comparable period in 2022. The increase in revenues related primarily to higher sales of ... Find real-time ONPH - Oncology Pharma Inc stock quotes, company profile, news and forecasts from CNN Business.

The reverse stock split will reduce the number of shares of Predictive Oncology’s common stock outstanding from 79,597,181 shares to approximately 3,979,860 shares, subject to adjustment for the ...Bank of America says this under-the-radar oncology stock can rally 180%. Published Fri, Aug 11 202311:35 AM EDT Updated Fri, Aug 11 202312:46 PM EDT. Pia Singh @pia_singh_.

ETFs positionnés sur Predictive Oncology Inc. Nom, Poids, Encours, Varia. 1 janv. Note Invest. VANGUARD TOTAL STOCK MARKET ...Predictive Oncology Inc. (NASDAQ: POAI) Stock Price as of July 16: $1.15 Number of Hedge Fund Holders: 2. Predictive Oncology Inc. (NASDAQ: POAI) ranks 10th on the list of 10 best one dollar ...Get a real-time Predictive Oncology Inc. (POAI) stock price quote with breaking news, financials, statistics, charts and more.The all-time high Predictive Oncology stock closing price was 27200.00 on November 09, 2015. The Predictive Oncology 52-week high stock price is 13.88, which is 385.3% above the current share price. The Predictive Oncology 52-week low stock price is 2.47, which is 13.6% below the current share price. The average Predictive Oncology stock price ...EAGAN, Minn., May 16, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused …Predictive Oncology Inc (POAI) stock is trading at $0.29 as of 2:08 PM on Friday, Mar 31, a gain of $0.01, or 3.39% from the previous closing price of $0.28. The stock has traded between $0.28 and $0.30 so far today. Volume today is below average. So far 218,615 shares have traded compared to average volume of 340,765 shares.Predictive Oncology Inc. EAGAN, Minn., May 16, 2022 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused ...

Their ZOM share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 3,421.1% from the stock's current price. View analysts price targets for ZOM or view top-rated stocks among Wall Street analysts.

The Predictive Oncology stock forecast for tomorrow is $ 2.88, which would represent a -0.32% loss compared to the current price. In the next week, the price of POAI is expected to increase by 14.32% and hit $ 3.30. As far as the long-term Predictive Oncology stock forecast is concerned, here ...

Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...The estimated Net Worth of J Melville Engle is at least $103 Thousand dollars as of 24 May 2022. Mr Engle owns over 159,500 units of Predictive Oncology stock worth over $99,663 and over the last 14 years he sold POAI stock worth over $0. In addition, he makes $3,000 as Chairman & CEO at Predictive Oncology.Wall Street Stock Market & Finance report, prediction for the future: You'll find the Predictive Oncology share forecasts, stock quote and buy / sell signals below. According to present data Predictive Oncology's POAI shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists).In the world of prophecy and spirituality, Perry Stone is a well-known figure who has gained a significant following for his insights into future events. One of Perry Stone’s notable predictions revolves around economic shifts and a possibl...Predictive Oncology to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on Tuesday, November 14, 2023 GlobeNewswire 11d 3 AI Stocks Worth Buying Now for Multibagger ...Predictive Oncology Inc. Common Stock (POAI) Stock Price, Quote, News & History | Nasdaq MY QUOTES: POAI Edit my quotes Predictive Oncology Inc. Common Stock (POAI) 0 Add to...Get the latest Predictive Oncology Inc (POAI) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Find the latest historical data for Predictive Oncology Inc. Common Stock (POAI) at Nasdaq.com.Press Releases. Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update. Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital. Predictive Oncology to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on Tuesday, November 14, 2023.A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its annual earnings. ... Predictive Oncology Inc. (POAI) Upgraded to Buy: What Does It Mean for the Stock?

Oncology Pharma Stock Forecast. Is Oncology Pharma Stock Undervalued? The current Oncology Pharma [ ONPH] share price is $0.0000. The Score for ONPH is 20, which is 60% below its historic median score of 50, and infers higher risk than normal. ONPH is currently trading in the 10-20% percentile range relative to its historical Stock Score levels.Predictive Oncology’s revenue increased by 45% to $455,000 in the most recent quarter, but the company continues to produce substantial losses. Thus, this is a relatively high-risk, high-upside ...The estimated Net Worth of J Melville Engle is at least $80.3 Thousand dollars as of 24 May 2022. Mr Engle owns over 159,500 units of Predictive Oncology stock worth over $77,289 and over the last 14 years he sold POAI stock worth over $0. In addition, he makes $3,000 as Chairman & CEO at Predictive Oncology.Nov 27, 2023 · The Price to Sales ratio or P/S is calculated as price divided by sales. After the P/E ratio, it's one of the most common valuation metrics. If the P/S ratio is 1, that means you're paying $1 for ... Instagram:https://instagram. pnc stocksbest option tradersfha lenders ohioit stock price Daniel Handley POAI stock SEC Form 4 insiders trading. Daniel has made over 4 trades of the Predictive Oncology stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 6,000 units of POAI stock worth $2,460 on 15 December 20226,000 units of POAI stock worth $2,460 on 15 December 2022Predictive Oncology Inc. PITTSBURGH, July 18, 2023 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and ... growing stocks to buymeta press release Daniel Handley POAI stock SEC Form 4 insiders trading. Daniel has made over 4 trades of the Predictive Oncology stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 6,000 units of POAI stock worth $2,460 on 15 December 20226,000 units of POAI stock worth $2,460 on 15 December 2022An increase of cash and equivalents from $25 million on March 31, 2022, to $28 million at quarter end, which represents a positive change of 12%. Q2 2022 financial results. Predictive Oncology’s ... romanee conti wine price Daniel Handley POAI stock SEC Form 4 insiders trading. Daniel has made over 4 trades of the Predictive Oncology stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 6,000 units of POAI stock worth $2,460 on 15 December 20226,000 units of POAI stock worth $2,460 on 15 December 2022View the latest Predictive Oncology Inc. (POAI) stock price, news, historical charts, analyst ratings and financial information from WSJ.